𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma

✍ Scribed by Kudelka, A.; Edwards, C.; Freedman, R.; Wallin, B.; Hord, M.; Howell, E.; Harper, K.; Raber, M.; Kavanagh, J.

Book ID
123582198
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
178 KB
Volume
29
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II study of intravenous exatecan
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma
✍ Francisco J. Esteva; Edgardo Rivera; Massimo Cristofanilli; Vicente Valero; Mela 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract ## BACKGROUND The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline‐resistant and taxane‐resistant, metastatic breast carcinoma. ## METHODS All patients had clinical evi

A Phase II trial of aprinocarsen, an ant
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinoma
✍ Ranjana Advani; Prema Peethambaram; Bert L. Lum; George A. Fisher; Lynn Hartmann 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND It has been postulated that protein kinase C α (PKC‐α) plays a pivotal role in signal transduction in tumor cancer cells. Aprinocarsen, a 20‐base antisense oligonucleotide, has shown ability to inhibit PKC‐α protein expression and inhibit tumor growth in human xenograft m